Spleen-derived dendritic cells engineere
β
Katsuyoshi Furumoto; Shigeki Arii; Seiji Yamasaki; Masaki Mizumoto; Akira Mori;
π
Article
π
2000
π
John Wiley and Sons
π
French
β 461 KB
π 1 views
The major goal in cancer immunotherapy is the induction of tumor-specific T lymphocytes capable of killing tumor cells. As both dendritic cells (DCs) and interleukin-12 (IL-12) can play immunostimulatory roles in vivo, the use of a combination of these has become a promising approach. In the present